Centrum Medyczne All-Med Badania Kliniczne — Clinical Trial Site

70 Registered trials

17 Currently recruiting

Organisation

Centrum Medyczne All-Med Badania Kliniczne

Location

Cracow, Poland

Identifier

ORG-100044304

Address

Ul. Henryka Sienkiewicza 23, 30-033, Poland

Departments

-
#412: Centrum Medyczne All-Med Badania Kliniczne
#45014
40092: Centrum Medyczne All-Med Badania Kliniczne
5201: Pulmonology
616005: pulmonology
Alergologia
All-Med
Centrum Medyczne "All-Med" BADANIA KLINICZNE
CENTRUM MEDYCZNE „ALL-MED”
Centrum Medyczne All-Med Badania Kliniczne
Centrum Medyczne All-Med, ul. Henryka Sienkiewicza 23, 30-03
Centrum Medyczne All-Med, ul. Henryka Sienkiewicza 23, 30-03( #1)
Centrum Medyczne All-Med. Badania Kliniczne
Dermatology
Dermatology Department
N/A
NA
Not applicable
Outpatient Clinic

Clinical trials at this site (70)

Search interface

A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherap… Ended

2022-502653-34-01 Atopic dermatitis and moderate-to severe atopic hand ec 11 2024-05-30
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Ended

2022-502481-24-00 Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) 4 2024-05-23
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject… Ended

2023-505842-24-00 Moderate to Severe Plaque Psoriasis 5 2024-05-07
"Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended

2023-505543-39-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-02-12
A research study to see how well new weekly medicine IcoSema, which is a combination of insulin icodec and semaglutide, controls blood sugar… Ended

2022-502484-38-00 Type 2 diabetes 5 2024-02-07
A study to evaluate the efficacy and safety of Clascoterone solution in treatment of male pattern hair loss. Ended

2023-504421-39-00 Androgenetic Alopecia 5 2023-11-21
A trial to evaluate the efficacy and safety of different doses of LEO 138559 in adults with moderate-to-severe atopic dermatitis. Ended

2022-500777-14-00 Atopic Dermatitis 4 2023-11-06
A multicentre, randomised, double-blind, placebo-controlled, 12-week parallel-group trial to evaluate the efficacy and safety of oral BP1.78… Ended

2022-502045-10-00 Atopic dermatitis 4 2023-08-11
A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Modera… Ended

2022-502575-30-00 Atopic Dermatitis 5 2023-05-23
A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-2) Ended

2023-507665-25-00 Severe Eosinophilic asthma 5 2023-04-25
Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended

2022-501063-41-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2023-04-20
An efficacy and safety study of HRO350 in patients with mild-to-moderate psoriasis (the ‘HeROPA’ study) Ended

2022-501850-12-00 Psoriasis 4 2023-03-15
Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma Ended

2023-504648-33-00 Oral Corticosteroid Dependent Asthma 5 2022-07-19
A study comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF5993 With the Fixed Dose Dual Combination CHF153… Ended

2023-510172-31-00 Chronic obstructive pulmonary disease (COPD) 5 2022-04-22
Study to assess efficacy, safety, and tolerability of Tozorakimab in patients with symptomatic chronic obstructive pulmonary disease (COPD) … Ended

2023-503572-24-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2022-03-02
A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Ended

2023-507093-40-00 Chronic Obstructive Pulmonary Disease (COPD) 4 2022-01-27
A study of GSK3511294 (Depemokimab) in participants who were previously enrolled in 206713 or 213744; Open-Label Extension Ended

2023-505203-23-01 Severe asthma with an eosinophilic phenotype 5 2021-07-26
The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy Ended

2023-510174-13-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2021-06-17
The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD) Ended

2023-510175-60-00 Chronic obstructive pulmonary disease (COPD) and Chron 5 2021-06-16
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experien… Ended

2023-507415-35-00 Psoriatic Arthritis 5 2021-01-15
Study of IMG-007 in Participants with Moderate to Severe Atopic Dermatitis Ended

2023-505735-13-01 Atopic dermatitis 9
A clinical study comparing different doses of a potential new medicine with an inactive medicine for patients with moderate to severe psoria… Ended

2023-508992-35-00 Plaque Psoriasis 4